These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 32336420)

  • 1. Tagraxofusp for Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Hammond D; Pemmaraju N
    Hematol Oncol Clin North Am; 2020 Jun; 34(3):565-574. PubMed ID: 32336420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tagraxofusp as treatment for patients with blastic plasmacytoid dendritic cell neoplasm.
    Lee SS; McCue D; Pemmaraju N
    Expert Rev Anticancer Ther; 2020 Jul; 20(7):543-550. PubMed ID: 32460559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tagraxofusp, the first CD123-targeted therapy and first targeted treatment for blastic plasmacytoid dendritic cell neoplasm.
    Economides MP; McCue D; Lane AA; Pemmaraju N
    Expert Rev Clin Pharmacol; 2019 Oct; 12(10):941-946. PubMed ID: 31465247
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations.
    Pemmaraju N; Madanat YF; Rizzieri D; Fazal S; Rampal R; Mannis G; Wang ES; Foran J; Lane AA
    Leuk Lymphoma; 2024 May; 65(5):548-559. PubMed ID: 38391126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Jain A; Sweet K
    J Natl Compr Canc Netw; 2023 May; 21(5):515-521. PubMed ID: 37156483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tagraxofusp, a novel CD123-directed cytotoxin to treat blastic plasmacytoid dendritic cell neoplasm.
    Tandon A; Zhang Y; Sokol L
    Drugs Today (Barc); 2019 Dec; 55(12):735-742. PubMed ID: 31942876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tagraxofusp for blastic plasmacytoid dendritic cell neoplasm.
    Luskin MR; Lane AA
    Haematologica; 2024 Jan; 109(1):44-52. PubMed ID: 36951152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of tagraxofusp in treating blastic plasmacytoid dendritic cell neoplasm (BPDCN).
    Alfayez M; Konopleva M; Pemmaraju N
    Expert Opin Biol Ther; 2020 Feb; 20(2):115-123. PubMed ID: 31801379
    [No Abstract]   [Full Text] [Related]  

  • 9. FDA Approval Summary: Tagraxofusp-erzs For Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Jen EY; Gao X; Li L; Zhuang L; Simpson NE; Aryal B; Wang R; Przepiorka D; Shen YL; Leong R; Liu C; Sheth CM; Bowen S; Goldberg KB; Farrell AT; Blumenthal GM; Pazdur R
    Clin Cancer Res; 2020 Feb; 26(3):532-536. PubMed ID: 31548341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blastic Plasmacytoid Dendritic Cell Neoplasm in Children.
    Li Y; Sun V; Sun W; Pawlowska A
    Hematol Oncol Clin North Am; 2020 Jun; 34(3):601-612. PubMed ID: 32336423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tagraxofusp followed by combined azacitidine and venetoclax in blastic plasmacytoid dendritic cell neoplasm: A case report and literature review.
    Samhouri Y; Ursu S; Dutton N; Tanvi V; Fazal S
    J Oncol Pharm Pract; 2021 Jun; 27(4):990-995. PubMed ID: 32847479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy Options for Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Haddadin M; Taylor J
    Hematol Oncol Clin North Am; 2020 Jun; 34(3):539-552. PubMed ID: 32336418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tagraxofusp and anti-CD123 in blastic plasmacytoid dendritic cell neoplasm: a new hope.
    Cangini D; Silimbani P; Cafaro A; Giannini MB; Masini C; Ghelli Luserna Di Rorà A; Simonetti G; Martinelli G; Cerchione C
    Minerva Med; 2020 Oct; 111(5):467-477. PubMed ID: 32955827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm.
    Pemmaraju N; Lane AA; Sweet KL; Stein AS; Vasu S; Blum W; Rizzieri DA; Wang ES; Duvic M; Sloan JM; Spence S; Shemesh S; Brooks CL; Balser J; Bergstein I; Lancet JE; Kantarjian HM; Konopleva M
    N Engl J Med; 2019 Apr; 380(17):1628-1637. PubMed ID: 31018069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tagraxofusp, a first-in-class CD123-targeted agent: Five-year postapproval comprehensive review of the literature.
    Jen WY; Konopleva M; Pemmaraju N
    Cancer; 2024 Jul; 130(13):2260-2271. PubMed ID: 38620053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Updates in Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).
    Economides MP; Rizzieri D; Pemmaraju N
    Curr Hematol Malig Rep; 2019 Dec; 14(6):515-522. PubMed ID: 31853773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating tagraxofusp for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN).
    Wilson NR; Pemmaraju N
    Expert Opin Pharmacother; 2022 Mar; 23(4):431-438. PubMed ID: 35060807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Case of Cutaneous Blastic Plasmacytoid Dendritic Cell Neoplasm Treated With a Bcl-2 Inhibitor.
    Egger A; Coello D; Kirsner RS; Brehm JE
    J Drugs Dermatol; 2021 May; 20(5):550-551. PubMed ID: 33938687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Pemmaraju N; Sweet KL; Stein AS; Wang ES; Rizzieri DA; Vasu S; Rosenblat TL; Brooks CL; Habboubi N; Mughal TI; Kantarjian H; Konopleva M; Lane AA
    J Clin Oncol; 2022 Sep; 40(26):3032-3036. PubMed ID: 35820082
    [No Abstract]   [Full Text] [Related]  

  • 20. Hematopoietic Cell Transplant for Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Kharfan-Dabaja MA; Cherry M
    Hematol Oncol Clin North Am; 2020 Jun; 34(3):621-629. PubMed ID: 32336425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.